Enpath (NASDAQ:NPTH)
Historical Stock Chart
From Jun 2019 to Jun 2024
Enpath Medical Receives FDA Marketing Clearance for Steerable
Sheath
Announces Exclusive License & Supply Agreement
MINNEAPOLIS, July 21 /PRNewswire-FirstCall/ -- Enpath Medical Inc.
(NASDAQ:NPTH) announced today that it has received FDA marketing clearance for
the Company's steerable sheath and has signed an exclusive license and supply
agreement with Bard Electrophysiology, a division of C. R. Bard, Inc. ("Bard")
for distribution of this product in the electrophysiology ("EP") market.
Although terms of the agreement were not disclosed, the Company stated the
agreement was subject to the completion of intellectual property due diligence
and Enpath attaining CE mark approval for the device.
"We are enthusiastic about this new opportunity because we believe Bard is well
positioned in the EP market, in part through its long-term focus on the
therapeutic treatment of cardiac arrhythmias," said James D. Hartman, Chairman
and CEO of Enpath. "Enpath's steerable sheath technology will enhance the
delivery of diagnostic and therapeutic devices in the heart. Therapeutic EP is
a large and rapidly growing market and it fits directly with Enpath's mission
to develop innovative delivery systems that improve the quality of patient
care."
The Food and Drug Administration 510(k) marketing clearance is for Enpath's
steerable sheath as a stand-alone device for a number of procedural indications
including interventional coronary, peripheral vascular and carotid artery
access. The Company is in early discussions with other potential partners
regarding distribution of iterations of the product for other attractive market
segments.
About Enpath Medical
Enpath Medical, Inc., headquartered in Plymouth, Minnesota, is a leader in the
design, development, manufacture and marketing of percutaneous delivery systems
and stimulation leads technologies. Its products include venous vessel
introducers, epicardial and endocardial stimulation leads, safety needles and
other products for use in pacemaker, defibrillator, catheter and infusion port
procedures as well as neuromodulation and hearing restoration markets. Its
products are sold worldwide through partnering relationships with other medical
device companies.
Safe Harbor
This news release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Certain important factors could cause
results to differ materially from those anticipated by some statements made
herein. All forward-looking statements involve risks and uncertainties. A
number of factors that could cause results to differ materially are discussed
in our Annual Report on Form 10-K for the year ended December 31, 2004, as well
as in our quarterly reports on Form 10-Q and Current Reports on Form 8-K. Among
the factors that could cause results to differ materially are the following:
the ability of Enpath and Bard to successfully negotiate and execute a
definitive license and supply agreement; the ability of Enpath to obtain FDA
marketing approval or clearance for its steerable sheath, the ability of Enpath
to complete the integration of the BCI operations; Enpath's dependence upon a
limited number of key customers for its revenue; Enpath's ability to complete
development of its Myopore Rx steroid epicardial lead and FasTac Flex delivery
tool and obtain FDA and European approval to market these devices; the ability
of Enpath and its distribution partners to successfully introduce the Myopore
Rx and FasTac Flex; the ability of Enpath's customers to successfully develop
and market therapies that utilize the Company's advanced delivery systems;
Enpath's dependence upon licensing agreements with third parties for the
technology underlying some of its products; Enpath's ability to effectively
manufacture its products, including the new Myopore Rx steroid lead and the
FasTac Flex delivery device, in anticipated required quantities; Enpath's
ability to develop or acquire new products to increase its revenues; Enpath's
ability to attract and retain key personnel; introduction of competitive
products; Enpath's ability to successfully protect its intellectual property
against misappropriation or claims of infringement by third parties; government
regulatory matters; economic conditions; and Enpath's ability to raise capital.
All forward- looking statements of Enpath, whether written or oral, and whether
made by or on behalf of Enpath, are expressly qualified by these cautionary
statements. In addition, Enpath disclaims any obligation to update
forward-looking statements to reflect events or circumstances after the date
hereof.
DATASOURCE: Enpath Medical, Inc.
CONTACT: Jim Hartman of Enpath Medical, Inc., +1-763-577-2212, or
Investors, Doug Sherk, +1-415-896-6820, or Jennifer Beugelmans,
+1-415-896-6820, both of EVC Group
Web site: http://www.enpathmed.com/